Send the following on WhatsApp
Continue to Chat抑制 PD-1 與 FcγR 結合來抗肺癌!BeiGene 免疫新藥三期臨床達試驗終點 https://geneonline.news/tislelizumab-phase-3-trial/?variant=zh-cn
抑制 PD-1 與 FcγR 結合來抗肺癌!BeiGene 免疫新藥三期臨床達試驗終點 https://geneonline.news/tislelizumab-phase-3-trial/?variant=zh-cn